Frontiers in Pharmacology
Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.
Al-Odat, O., von Suskil, M., Chitren, R., Elbezanti, W., Srivastava, S., Budak-Alpddogan, T., Jonnalagadda, S., Aggarwal, B., & Pandey, M. (2021). Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma. Frontiers in pharmacology, 12, 699629. https://doi.org/10.3389/fphar.2021.699629
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.